# Indi-Blade (NCT05200988)

> Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05200988
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: The Netherlands Cancer Institute
- Conditions: Urothelial Carcinoma; Bladder Cancer
- Interventions: Ipilimumab + nivolumab
- Enrollment: 50
- Primary outcome: Efficacy defined as bladder-intact event-free survival (BI-EFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 9
- Podcasts: 6
- YouTube: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=indi-blade-nct05200988

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05200988", "email": "<work email>"}; the inbox owner confirms by the emailed link.